Latest Earnings Results: Q3 '26
Estimated EPS
-$0.52
Reported EPS
-$0.52
Surprise
+0.64%
Estimated Rev
$34.72M
Reported Rev
$35.51M
Surprise
+2.26%
• Reported GAAP EPS of -$0.52 down -57.58% YoY • Reported revenue of $35.51M up 30.31% YoY • Beta Bionics estimates FY2026 total revenue of approximately $124M to $126M, gross margin of 58.5% to 59.5%, and 37% to 39% of new patient starts reimbursed through PBP.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.50 | -- | -- | N/A |
Q3 '26 | -$0.52 | -$0.52 | 0.64% | BEAT |
Q2 '26 | -$0.58 | -$0.53 | 8.78% | BEAT |
Q1 '26 | -$0.50 | -$0.49 | 2.53% | BEAT |
Q4 '25 | -$0.40 | -$0.30 | 25.59% | BEAT |